Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma
2022年10月11日 - 2:00PM
Roche launches PRAME (EPR20330) Antibody to identify PRAME protein
expression in patients that may have melanoma
- The PRAME (EPR20330)
Antibody evaluates PRAME protein expression from patients with
suspected melanoma.
- Understanding if the PRAME
protein is expressed helps enable more informed clinical decisions
and may improve patient outcomes.
- The PRAME (EPR20330)
Antibody is the latest addition to Roche’s robust dermatology
portfolio with more than 50 dermatology biomarkers designed to meet
a broad range of diagnostic needs.
Basel, 11 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
today announced the launch of Anti-PRAME (EPR 20330) Rabbit
Monoclonal Primary Antibody to identify PRAME protein expression in
tissue samples from patients with suspected melanoma. Because the
PRAME (PReferentially expressed Antigen in MElanoma) protein is
expressed in most melanomas, the PRAME (EPR20330) Antibody* is used
as an aid to differentiate between benign and malignant lesions to
help improve diagnostic decisions. If PRAME expression is detected,
this suggests that the lesion is malignant. “Every four minutes,
one person dies from skin cancer. However, when detected early,
localised melanoma is highly curable with a simple surgical
excision,” said Thomas Schinecker, CEO of Roche Diagnostics.
“Identifying this critical biomarker helps clinicians determine if
their patient has melanoma. We’re proud to add the PRAME assay to
our already comprehensive test menu of dermatology biomarkers that
help inform a patient’s diagnosis and treatment.”Melanoma is an
aggressive skin cancer that originates from melanocytes, which are
cells in the skin and eyes that produce and contain melanin.
Melanoma develops when unrepaired DNA damage to melanocytes
triggers mutations that cause the melanocytes to grow rapidly and
form malignant tumours. When detected early, the 5-year survival
rate is 99 percent.1 The first test that is used to evaluate a
potential melanocytic lesion is a hematoxylin and eosin (H&E)
stain of the patient’s tissue sample. However, not all melanomas
are easily diagnosed using H&E alone. Studies suggest that
detection of PRAME expression by immunohistochemistry (IHC)
complements findings from routinely used tests and enables more
informed clinical decisions and improved patient outcomes.2-4 In
particularly challenging cases, use of PRAME IHC may highlight
abnormal cells expressing the PRAME protein and provide more
confidence in diagnosis of melanoma.More information about PRAME
will be presented at the International Academy of Pathology 2022
World Congress in Sydney, Australia on 14 October 2022 in a session
titled “The diagnostic approach to melanocytic
lesions”.About the Anti-PRAME (EPR 20330)
Rabbit Monoclonal Primary AntibodyThe
PRAME (EPR20330) Antibody is fully automated on the full line of
Roche BenchMark IHC/ISH instruments. This antibody is validated for
use using OptiView DAB IHC Detection, ultraView Universal DAB
Detection & ultraView Universal Alkaline Phosphatase Red
Detection Kits giving added flexibility to laboratories and
pathologists' preferences.
About Roche Founded in 1896 in Basel,
Switzerland, as one of the first industrial manufacturers of
branded medicines, Roche has grown into the world’s largest
biotechnology company and the global leader in in-vitro
diagnostics. The company pursues scientific excellence to discover
and develop medicines and diagnostics for improving and saving the
lives of people around the world. We are a pioneer in personalised
healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care
for each person we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the
clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the thirteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan. For more information, please visit
www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
*Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary
AntibodyReferences[1] American Cancer Society. [2]
Lezcano, C. et al. PRAME expression in melanocytic tumors. Am J
Surg Pathol 2018;42(11):1456-1465.[3] Lezcano, C. et al. PRAME
immunohistochemistry as an ancillary test for the assessment of
melanocytic lesions. Surg Pathol Clin 2021 Jun;14(2):165-175[4]
Lezcano, C. et al. Immunohistochemistry for PRAME in the
distinction of nodal nevi from metastatic melanoma. Am J Surg
Pathol 2020;44(4):503-508.
Roche Group Media RelationsPhone: +41 61 688
8888 / e-mail: media.relations@roche.com
Hans Trees, PhDPhone: +41 61 687
41 47 |
Nathalie
AltermattPhone: +41 61 687 43 05 |
Karsten
KleinePhone: +41 61 682 28 31 |
Nina
MählitzPhone: +41 79 327 54 74 |
Dr.
Barbara von SchnurbeinPhone: +41 61 687 89 67 |
Sileia
Urech Phone: +41 79 935 81 48 |
Roche Investor Relations
Dr. Bruno
Eschli Phone: +41 61 68-75284 e-mail:
bruno.eschli@roche.com |
Dr.
Sabine BorngräberPhone: +41 61 68-88027 e-mail:
sabine.borngraeber@roche.com |
Dr.
Birgit MasjostPhone: +41 61 68-84814e-mail:
birgit.masjost@roche.com |
Dr.
Gerard Tobin Phone: +41 61 68-72942 e-mail:
gerard.tobin@roche.com |
|
|
Investor Relations North America
Loren
Kalm Phone: +1 650 225 3217 e-mail:
kalm.loren@gene.com |
|
Roche (LSE:0QQ6)
過去 株価チャート
から 3 2024 まで 4 2024
Roche (LSE:0QQ6)
過去 株価チャート
から 4 2023 まで 4 2024